The Preanalytical Stability of Emerging Cannabinoid Analogs (Delta-8 THC and its Metabolites, Delta-10 THC, and Carboxy-HHC) in Urine.

Abstract

There has been a surge in the presence and use of cannabinoids since the federal legalization of hemp (Agricultural Improvement Act of 2018). This increase is attributed not only to the use of ∆9-tetrahydrocannabinol (∆9-THC) and cannabidiol (CBD), the most abundant phytocannabinoid components of cannabis and hemp, respectively, but with the use of many other emerging THC analogs. Structurally, these analogs are similar to ∆9-THC. Urine specimens for drug analysis are often collected offsite and transported to a laboratory for analysis. Screening assays are usually the first step in urine drug testing. These assays are usually qualitative and automated, which for negative specimens, reduces cost and reporting time. The stability of ∆9-THC and its metabolites has been known for some time, however the stability of emerging analogs has not been elucidated, therefore assuming equivalent storage stability can be erroneous. Previous work assessed the cross-reactivity of ∆8-THC and its major metabolites, the ∆1°-THC chiral analogs, and the chiral 11-COOH-HHC analogs. Stability was assessed for each analyte at a concentration two times greater than the analytes determined decision point. Samples were prepared in drug-free urine at three different pHs (4.5, 7, and 9) and stored at three different temperatures (4°C, 20°C, and 45°C) in triplicate. Samples were analyzed utilizing the LZI Cannabinoids (cTHC) Enzyme Immunoassay cannabinoid screening kit calibrated at the 25 ng/mL cutoff. Overall, the cannabinoid analogs produced diminishing instrument responses depending on pH and temperature. The parent analogs were not detected after a single day at 45°C regardless of pH. In general, carboxylic acid analogs at the acidic pH (4.5) produced diminished instrument responses when compared to their counterparts stored at neutral (7) and basic (9) pH. The time, storage temperature, and pH of urine specimens may affect the screening results of specimens collected for cannabinoid drug screening.